Next Article in Journal
Antibiotic Prescribing in Outpatient Settings: Rural Patients Are More Likely to Receive Fluoroquinolones and Longer Antibiotic Courses
Next Article in Special Issue
Impact of Persistent Multidrug-Resistant Gram-Negative Bacteremia on Clinical Outcome and Mortality
Previous Article in Journal
Antimicrobial Activities and Mode of Flavonoid Actions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 2
10.3390/antibiotics12020226
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Development of a Clinical Score to Stratify the Risk for Carbapenem-Resistant Enterobacterales Bacteremia in Patients with Cancer and Hematopoietic Stem Cell Transplantation

by
Fabián Herrera
1,*,
Diego Torres
1,
Ana Laborde
2,
Lorena Berruezo
3,
Rosana Jordán
4,
Inés Roccia Rossi
5,
Alejandra Valledor
6,
Patricia Costantini
7,
Miguel Dictar
8,
Andrea Nenna
9,
María Laura Pereyra
10,
Sandra Lambert
11,
José Benso
12,
Fernando Poletta
1,
María Luz Gonzalez Ibañez
2,
Nadia Baldoni
3,
María José Eusebio
4,
Fiorella Lovano
5,
Laura Barcán
6,
Martín Luck
7,
Agustina Racioppi
8,
Lucas Tula
11,
Fernando Pasterán
13,
Alejandra Corso
13,
Melina Rapoport
13,
Federico Nicola
1,
María Cristina García Damiano
2,
Ruth Carbone
3,
Renata Monge
4,
Mariana Reynaldi
5,
Graciela Greco
6,12,
Marcelo Bronzi
7,
Sandra Valle
8,
María Laura Chaves
9,
Viviana Vilches
10,
Miriam Blanco
11 and
Alberto Ángel Carena
1,† on behalf of the Argentine Group for the Study of Bacteremia in Cancer and Stem Cell Transplant (ROCAS) Studyadd Show full author list remove Hide full author list
1
Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires C1431, Argentina
2
FUNDALEU, Buenos Aires C1114, Argentina
3
Hospital HIGA Rodolfo Rossi, La Plata B1902, Argentina
4
Hospital Británico de Buenos Aires, Buenos Aires C1280, Argentina
5
Hospital HIGA Gral San Martín, La Plata B1900, Argentina
6
Hospital Italiano de Buenos Aires, Buenos Aires C1199, Argentina
7
Instituto de Oncología Angel H. Roffo, Buenos Aires C1417, Argentina
8
Instituto Alexander Fleming, Buenos Aires C1426, Argentina
9
Hospital Municipal de Oncología Marie Curie, Buenos Aires C1405, Argentina
10
Hospital Universitario Austral, Buenos Aires B1629, Argentina
11
Hospital El Cruce, Buenos Aires B1888, Argentina
12
Hospital Italiano de San Justo, Buenos Aires C1198, Argentina
13
Servicio de Antimicrobianos, ANLIS Malbrán, Buenos Aires C1282, Argentina
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
†
All members of the ROCAS Group are listed in the Acknowledgements section.
Antibiotics 2023, 12(2), 226; https://doi.org/10.3390/antibiotics12020226
Submission received: 10 December 2022 / Revised: 6 January 2023 / Accepted: 16 January 2023 / Published: 20 January 2023
(This article belongs to the Special Issue The Issue of Multidrug-Resistant Pathogens in Nosocomial Infections)
Browse Figures
Review Reports Versions Notes

Abstract

:
Identifying the risk factors for carbapenem-resistant Enterobacterales (CRE) bacteremia in cancer and hematopoietic stem cell transplantation (HSCT) patients would allow earlier initiation of an appropriate empirical antibiotic treatment. This is a prospective multicenter observational study in patients from 12 centers in Argentina, who presented with cancer or hematopoietic stem-cell transplant and developed Enterobacterales bacteremia. A multiple logistic regression model identified risk factors for CRE bacteremia, and a score was developed according to the regression coefficient. This was validated by the bootstrap resampling technique. Four hundred and forty-three patients with Enterobacterales bacteremia were included: 59 with CRE and 384 with carbapenem-susceptible Enterobacterales (CSE). The risk factors that were identified and the points assigned to each of them were: ≥10 days of hospitalization until bacteremia: OR 4.03, 95% CI 1.88–8.66 (2 points); previous antibiotics > 7 days: OR 4.65, 95% CI 2.29–9.46 (2 points); current colonization with KPC-carbapenemase-producing Enterobacterales: 33.08, 95% CI 11.74–93.25 (5 points). With a cut-off of 7 points, a sensitivity of 35.59%, specificity of 98.43%, PPV of 77.7%, and NPV of 90.9% were obtained. The overall performance of the score was satisfactory (AUROC of 0.85, 95% CI 0.80–0.91). Finally, the post-test probability of CRE occurrence in patients with none of the risk factors was 1.9%, which would virtually rule out the presence of CRE bacteremia.

1. Introduction

Over the last two decades, there has been a worldwide emergence of CRE, which has become one of the most challenging threats to the healthcare-system. The most common resistance mechanism is the presence of a carbapenemase gene, which is mostly found in Klebsiella pneumoniae. However, the genes encoding for carbapenemases are typically located on plasmids and can be transferred both within bacterial species and across different species and genera. These plasmids often coharbor resistance mechanisms against other antimicrobial classes, such as fluoroquinolones, aminoglycosides, tetracyclines, and trimethoprim-sulfamethoxazole, rendering bacteria resistant to multiple drugs [1,2]. From 1997 to 2016, the SENTRY Antimicrobial Surveillance Program collected Enterobacterales isolates from 42 countries located in four main geographic regions. Statistically significant increases in CRE rates have been observed worldwide, with the highest rates reported in Latin America. Although KPC-encoding genes were the most prevalent in several geographic areas, Enterobacterales species that carry genes encoding NDM and OXA-48 variants are on the rise. An increase has also been observed in Enterobacterales isolates that harbor ≥2 carbapenemase genes [3,4,5]. This problematic scenario is a challenge to antimicrobial treatment because of the limited therapeutic options evidenced by the poor outcomes of carbapenemase-producing Enterobacterales (CPE) infections [6].
The epidemiology of multidrug-resistant gram-negative bacteria (MDR-GNB) in cancer and HSCT may differ according to the pathogen, geographic region, country and among health-care centers in the same country.
In this context, an intercontinental study on bacteremias due to GNB in HSCT in 65 centers from 25 countries provided important data. CRE was found in 8.4% of the total Enterobacterales, with 25% being K. pneumoniae isolates. Regarding the resistance to carbapenems, a substantial difference was observed among the regions of Europe (20.7% in the southeast vs. 4.9% in the northwest, p < 0.0001) [7]. Likewise, a multicenter study conducted in 9 Italian hospitals found that among K. pneumoniae strains, 34.9% were resistant to carbapenems [8]. The Argentine Group for the Study of Bacteremia in Cancer and Stem Cell Transplant (ROCAS) registered 1277 bacteremia episodes in patients with hematologic malignancies (HM) and HSCT, and 60% of the isolates were GNB (75% Enterobacterales). The resistance to meropenem in patients with HM and HSCT was 18.4% vs. 26.4% (p = 0.016), which was mainly mediated by KPC-carbapenemase-producing Enterobacterales (KPC-CPE) [9].
The overall 30-day mortality rates after CRE bacteremia in patients with HM and HSCT range from 50% to 72.7% [10,11,12,13]. A large study on Enterobacterales bacteremia in cancer and HSCT patients carried out in Argentina found that CRE bacteremia was independently associated with higher 30-day mortality (OR: 7.4; 95% CI: 3.4–15.9; p < 0.001) [14].
Several risk factors for CRE bacteremia have been identified in hematological patients. They include rectal colonization by CRE, recent use of carbapenems and other antibiotics, intensive care unit (ICU) admission, acute myeloid leukemia, glucocorticoids, longer stay of current hospitalization before the episode, etc. [15,16,17,18]. However, some of the abovementioned risk factors have not been precisely defined in the literature, such as length of hospital stay and rectal colonization before bacteremia, or the duration of antibiotic treatment until bacteremia. Therefore, we developed and validated a clinical score to accurately define the risk of cancer and HSCT patients developing CRE bacteremia.

2. Results

A total of 443 patients with Enterobacterales bacteremia were included: 266 (60%) had HM (with acute leukemia, 39.5%, and lymphoma, 25.5%, being the most frequent); 92 (20.8%) had solid tumors (ST); and 85 (19.2%) had undergone HSCT (42.4% allogeneic). Recently diagnosed was the most frequent stage of underlying cancer (35.9%), and 310 (70%) patients had neutropenia, 87.4% were classified as high-risk by their MASCC score, with a median neutropenia duration of 12 days. Two hundred and thirty-three (53.3%) patients had been hospitalized recently (1 month prior to bacteremia) and 203 (45.8%) had recently used antibiotics. The baseline differences between patients with CSE and CRE bacteremia are detailed in Table 1.
Most isolates were E. coli (204, 46%) and Klebsiella spp. (182, 41.1%), and 171 (38.6%) microorganisms were MDR, with extended-spectrum β-lactamases (ESBL)-producing Enterobacterales (108, 24.4%) and KPC-CPE (54, 12.2%) being the most frequent. No outbreaks due to MDR-GNB were observed during the study period. The microbiological characteristics of CSE and CRE bacteremia are described in Figure 1 and Figure 2.
Two hundred and ninety-six (66.8%) of the bacteremia cases were classified as nosocomial infections, and the length of hospitalization until bacteremia was 9 days (interquartile range (IQR): 0–15). Three hundred and twenty (72.2%) bacteremia cases had a clinical source, with abdominal being the most frequent (129, 29.1%). The empirical antibiotic treatment (EAT) was adequate in 85.8% of the patients, with monotherapy (321, 72.4%) being the most frequent. One hundred and thirteen patients (25.5%) developed shock, and 34 (7.7%) had breakthrough bacteremia. The 7-day and 30-day mortality was 14.9% and 22.6%, respectively, and was related to infection in more than 70% of the cases. Marked differences were observed in the treatment and outcomes between the two groups, as highlighted in Table 2.
Univariate analyses identified eight risk factors for CRE bacteremia, and multivariate analysis showed that three were independently associated. To predict CRE bacteremia, a score was developed by assigning a point to each of these variables according to their regression coefficient, as shown in Table 3.
The sensitivity, specificity, likelihood ratios (LR) and post-test probability of CRE bacteremia for each cut-off point of the score are shown in Table 4.
No collinearity was observed between these variables. Using a cut-off value of 7 points, the score had a sensitivity of 35.59% (95% CI 26.3–49.1%), a specificity of 98.43% (95% CI 96.6–99.4%), a positive predictive value (PPV) of 77.7% (95% CI 59.5%–89.2%), and a negative predictive value (NPV) of 90.9% (95% CI 89.2%–92.3%). Internal validation was performed using the bootstrap resampling technique (1000 samples). We calculated the possible deviation of ß-coefficients (bias) with their respective confidence intervals, and the results were compared in regard to both calibration and discrimination, with a very high similarity between them. This final model reported an area under the ROC curve (AUROC) of 0.85; 95% CI 0.79–0.90 and an AUROC of 0.85; 95% CI 0.80–0.91 for the internal validation. In the cases where none of the risk factors was identified, the negative LR was 0.12 and the post-test probability of presenting CRE bacteremia was 1.90%.

3. Discussion

Several score systems have been developed to more precisely define the risk for CRE infection and improve the clinical approach to reduce mortality, and to further avoid the unnecessary use of broad-spectrum antibacterial agents. In this regard, Gianella et al. designed a score to identify the risk factors for CR-K. pneumoniae bacteremia among rectal carriers in a multicenter prospective matched case-control study with 143 bacteremia episodes and 572 controls without infection. Admission to the ICU, abdominal invasive procedures, chemotherapy/radiation therapy, and the number of additional colonization sites were independent risk factors for CR-K. pneumoniae bacteremia. Since the score had a high NPV, they concluded that anti-CR-K. pneumoniae antibiotic coverage could be avoided in rectal carriers without the above risk factors, and who develop signs and symptoms of infection [19]. A few years later, Cano et al. validated this score in a cohort of 94 CR-K. pneumoniae rectal carriers [20]. Although the first study included immunosuppressed patients, the proportion with malignancies and neutropenia was low. The second study was carried out during a protracted outbreak of infections due to clonal KPC-K. pneumoniae, and bacteremia episodes only accounted for 50% of them. Since our study markedly differs in terms of the patient population, epidemiological characteristics, and risk factors, the results cannot be extrapolated to those of the previously described studies.
Gianella et al. conducted a study in 237 liver transplant patients screened for rectal CR-K. pneumoniae. The independent risk factors for CR-K. pneumoniae infection were renal replacement therapy, mechanical ventilation > 48 h, hepatitis C virus recurrence, and colonization with CR-K. pneumoniae at any time was the strongest variable [21]. As observed in the previous studies, the population’s characteristics differed from ours. In addition, although colonization was the risk factor most strongly associated with infection, this variable was not differentiated in terms of the time of occurrence. We found that only recent colonization with KPC-CPE was significantly associated with the risk of bacteremia.
Three retrospective single-center studies have been published, which propose risk prediction models for CRE infections and bacteremia in patients with HM and HSCT. Zhang et al. [22] performed a study in 734 patients (22 with CR-K. pneumoniae bacteremia). They did not identify the resistance mechanism to carbapenems (e.g., enzyme type such as KPC or OXA carbapenemases). The following three risk factors for CR-K. pneumoniae were identified: invasive mechanical ventilation, CR-K. pneumoniae rectal colonization and severe neutropenia. The risk score was considered adequate for the prediction of CR-K. pneumoniae bacteremia, with an AUROC of 0.753 (95% CI = 0.648–0.858). Nevertheless, the actual predictive performance of the model including sensitivity, specificity, PPV and NPV was not shown.
Wang et al. [23] conducted a 1:1 matched case-control study on intestinal carriers hospitalized in the HM unit and ICU who developed CRE bacteremia and compared them with those who did not develop CRE infection. A total of 42 cases were included. Gastrointestinal injury, tigecycline exposure and the carbapenem resistance score were independent risk factors for CRE bacteremia. The cut-off value of the model was 0.722, with the sensitivity, specificity and AUROC being 90.5%, 85.7% and 0.921, respectively. However, the number of cases was small and the model was developed in both the hematology and ICU department, which could lead to different epidemiology and risk factors for infection.
Wu et al. [24] performed a study on 392 patients with HM who were colonized with CR-GNB (Enterobacterales and non-fermenters GNB). Of these, 10.7% developed a confirmed CR-GNB infection (10.2% were bacteremia), and 36% developed a clinically diagnosed infection (presumed by their therapeutic response to antibiotics). However, some or several of these infection episodes could not be due to CR-GNB, and the risk was therefore overestimated. Moreover, infections caused by both Enterobacterales and non-fermenters CR-GNB were included, with a different risk of infection regarding intestinal colonization.
Our study differs from the three described above because it is prospective and multicentric, has a larger population of immunosuppressed patients, all with Enterobacterales bacteremia and with the identification of the CRE mechanism.
Identifying patients at risk for CRE has a significant clinical impact since adequate empirical treatments can be implemented early, thus reducing mortality. In our cohort, patients with CRE bacteremia compared with those with CSE bacteremia had significantly less adequate empirical treatment, more significant delay in initiating adequate antibiotic treatment before 24 h, and higher 7-day mortality and 30-day mortality. In this regard, several studies on CRE infections have shown that initial inadequate antimicrobial therapy was significantly associated with higher mortality, while adequate early antimicrobial therapy (administered within 24 h from blood culture collection) improved survival [13,15,25].
No randomized clinical trials have been completed to define the optimal treatment for CRE infections. The existing clinical evidence regarding treatment is based upon observational clinical data, in vitro data, and in vivo animal models. In recent years, new drugs have become available for the treatment of carbapenem-resistant infections, including, among others, ceftazidime–avibactam, meropenem–vaborbactam and imipenem–relebactam. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines recommend ceftazidime–avibactam or meropenem–vaborbactam for severe CRE infections if active in vitro [26]. On the other hand, the Infectious Diseases Society of America guidelines recommend ceftazidime–avibactam, meropenem–vaborbactam and imipenem–relebactam as the preferred treatment options for KPC-CRE infections outside of the urinary tract. However, empiric treatment recommendations are not provided [27]. Ceftazidime–avibactam provided the most extensive real-life data, and demonstrated superiority over other antibiotics for KPC-CRE infections. The larger studies included patients with HM, HSCT, and neutropenia, but they failed to analyze them separately from the total cohort [28,29,30]. A few studies that were exclusively focused on patients with HM have shown clinical benefits over other antibiotics [31,32].
There are encouraging data on treatment with the new ß-lactam/ß -lactamase inhibitor antibiotics, which highlights the early identification of patients with CRE infections.
We acknowledge several limitations of the present study. First, the population analyzed is heterogeneous in terms of cancer type and the presence of neutropenia. However, bloodstream infections in cancer patients may occur in those with even a minor degree of immunosuppression. Second, the data on previous or recent colonization with KPC-CPE may be underestimated because rectal swabs were collected at 11 centers. However, the center that did not perform any surveillance only represented 4.1% of the total cohort, which would therefore not change the interpretation of the results. Third, our score was developed in a cohort where the prevalent mechanism of carbapenem resistance was KPC production. We must determine whether it could also be applied to patients colonized with other types of carbapenemase-producing strains (i.e., MBL, OXA-48). Fourth, this score was developed in a population with a high prevalence of CRE. Therefore, the score could not be applied to areas where cancer patients had different epidemiology.
The strengths of our study rely on its being the first prospective, multicenter study carried out in cancer and HSCT patients, where a large number of Enterobacterales bacteremia episodes have been included. Risk factors for CRE were identified, and a risk score was developed and internally validated. As in our case, several studies have identified rectal colonization with KPC-CPE, recent use of antibiotics and a longer stay of current hospitalization before the episode of bacteremia as risk factors for CRE in different populations. However, our study was able to identify these variables more accurately according to the number of days (>7 days of antibiotics use prior to bacteremia and ≥10 days of hospitalization prior to bacteremia), and the time of occurrence of these risk factors (recent colonization with KPC-CPE). Patients with a cut-off value of 7 points had a specificity of 98.3%, a PPV of 77.7%, and an NPV of 90.9% for presenting CRE bacteremia, which is considered as high risk. However, the most relevant issue is that in patients with none of these risk factors, the negative LR was 0.12 and the post-test probability of presenting CRE bacteremia was 1.90%. Therefore, it could be useful to rule out CRE bacteremia, especially in regions with a lower CRE prevalence.
Another important point is that two of the identified risk factors may be modified with appropriate infection control measures and antimicrobial stewardship programs [33,34]. Likewise, the strategy of fecal microbiota transplantation for decolonization of patients with CRE is also promising [35,36].
To conclude, this risk score in cancer and HSCT patients could help avoid the use of broad-spectrum antibiotics in patients at a low risk of developing CRE bacteremia and help to prescribe an early optimal antibiotic regimen in high-risk patients in order to improve the outcome. Nevertheless, to clearly estimate the utility of this score in clinical practice, it must be validated in a prospective cohort.

4. Materials and Methods

4.1. Setting, Patients and Study Design

A multicenter prospective study was performed in 12 referral teaching centers (7 private and 5 public) that specialize in the care of oncological and transplant patients in Argentina. The patient characteristics and the medical treatment provided were similar in these centers.
All episodes of initial monomicrobial bacteremia (defined as the first episode of bacteremia experienced during an admission) caused by Enterobacterales in adult patients (≥18 years of age) that were managed as inpatients from May 2014 to June 2019 were included. Patients presented with (a) a solid tumor or HM treated with chemotherapy or biological agents (six months prior to admission) or they had been receiving steroids (at a dose equal to or higher than prednisone 20 mg daily or equivalent, for at least two weeks prior to admission); or (b) allogeneic HSCT (with graft versus host disease at any time or without this disease in the first two years) or autologous HSCT (in the first year post-transplant). Patients with polymicrobial bacteremia, and those receiving palliative care were excluded from the analysis. Patients were identified at the time of a positive blood culture and were then followed prospectively. Data were obtained from medical records (electronic and paper records depending on the center involved) and direct patient care, with a double check made with microbiological records from the laboratory. Clinical, microbiological, treatment, and outcome variables were evaluated. Empirical personalized antibiotic therapy was started based on the patient’s clinical and epidemiological features, and at the discretion of the attending physician. Patients were followed for 30 days after the episode (by direct patient care in hospitalized cases, or by phone calls in the case of discharged patients), or until the patient’s death, provided that it happened before (assessed by direct patient care in patients still hospitalized or by a local healthcare database in each center). The stage of the underlying cancer and immunosuppression in ST, HM and HSCT patients are outlined in A1, Appendix A.

4.2. Definitions

Neutropenia was defined as an absolute neutrophil count < 500 cells/mm3. High-risk febrile neutropenia was defined according to clinical variables and a Multinational Association for Supportive Care in Cancer (MASCC) score of < 21 [37]. The clinical source of infection was determined based on the isolation of the bacteria in the suspected source and/or the associated clinical signs and symptoms. Recent antibiotic use was defined as any antibiotic administered 30 days before the episode of bacteremia and for more than 48 h. Recent ICU admission was defined as an admission within 14 days prior to the episode of bacteremia and for at least 72 h. A central venous catheter was considered a risk factor when placed for at least 72 h before the episode of bacteremia. Colonization or infection with CRE was defined as “previous” when it occurred within six months before hospitalization, and “recent” when it was detected within one week of the episode of bacteremia.
Friedman et al. classified bacteremia as nosocomial, health-care-associated, or community-acquired [38]. Breakthrough bacteremia was defined as an episode of continuous or new-onset bacteremia in a patient receiving appropriate antibiotics for the microorganism that was recovered from blood cultures. The empirical antibiotic treatment (EAT) was adequate if one or more antibiotics were active in vitro against the isolated bacteria. In patients with ESBL-E, empirical therapy with piperacillin/tazobactam or cefepime alone was considered inadequate [39]. In patients with CSE or CRE, empirical therapy with tigecycline as the only active drug was considered inadequate. Response to treatment on day 7 of therapy was defined as the absence of fever and hypotension, and clinical improvement. Mortality was related to infection provided that there was microbiological, histological, or clinical evidence of active infection.

4.3. Microbiological Studies

Bacteremia was defined as the isolation of a pathogenic bacteria in at least one bottle of blood culture (BD BACTEC F Aerobic and Anaerobic, analyzed with BACTEC FX BD, BacTALERT 3D Biomerieux depending on the method available at each center), for a minimum incubation period of five days. MDR-GNB were defined as a GNB resistant to three or more of the following categories of antibiotics: carbapenems, piperacillin/tazobactam, third and fourth generation cephalosporins, aztreonam, fluoroquinolones, or aminoglycosides [40,41]. Microbiological identification and susceptibility testing were done with manual biochemical and microbiological methods, disk diffusion (according to the CLSI recommendations), and/or Etest, VITEK II Compact (bioMerieux), PHOENIX 100 BD (Becton Dickinson), VITEK MS (bioMerieux) and MALDI-TOF (Microflox from Bruker). Carbapenemase production was investigated in carbapenem-resistant bacteria using the modified Hodge method, disk synergy tests with a carbapenem disk placed close to the boronic acid disk test for KPC, and the EDTA disk for identification of metallo-β-lactamases. The presence of genes coding for blaKPC and blaOXA-48 was investigated by monoplex or multiplex polymerase chain reaction (PCR) using specific primers depending on the method available at each center. Multiplex PCR for blaVIM, blaNDM, blaIMP, blaKPC and blaOXA-48 was used to investigate 17 isolates at the National Reference Laboratory of Microbiology (ANLIS-Malbrán) [42]. In order to detect colonization with KPC, rectal swabs were routinely collected (once a week and in every pre-transplant evaluation) in 11 of the 12 centers included in the study, using chromogenic methods and/or PCR.

4.4. Statistical Analysis

To compare the characteristics, treatments, and outcomes of patients with CRE and CSE, the x2 test, Fisher’s exact test and Mann–Whitney U-test were used when indicated. To identify the risk factors for CRE that were included as variables in the score, a multiple logistic regression model (forward-stepwise selection) was used. Variables with a p < 0.05 in the univariate analysis were included in the multivariate model. For multivariate analysis, variables with a statistically significant association at p < 0.05 were used to develop the score. Weighted scores for each variable were calculated by dividing each regression coefficient by one-half of the smallest coefficient and rounding to the nearest integer [43]. A tetrachoric correlation model was used to evaluate collinearity. The calibration of the model was evaluated using the Hosmer–Lemeshow test, and the Nagelkerke and Cox/Snell R2 were calculated. The predictive performance of the model and the score was evaluated using sensitivity, specificity, PPV, NPV, and AUROC, with a value of 1.0 indicating perfect prediction. The post-test probability of the different values of the score was further assessed for predicting CRE, with a pre-test probability of 13.3% (data obtained from previous local, non-published analysis). The internal validation of the final model was assessed using the bootstrap resampling technique. For all tests, a 95% level of statistical significance was used. All tests were two-tailed. The analyses were performed with the SPSS and Stata 14.0 (Statacorp; College Station, TX, USA) software packages.

Author Contributions

Conceptualization, F.H., D.T. and A.Á.C.; methodology, F.H., D.T., A.Á.C. and F.P. (Fernando Poletta); software, D.T. and A.Á.C.; validation, A.Á.C. and F.P. (Fernando Poletta); formal analysis, A.Á.C. and F.P. (Fernando Poletta); investigation, A.L.; L.B. (Lorena Berruezo); R.J.; I.R.R.; A.V.; P.C.; M.D.; A.N.; M.L.P.; S.L.; J.B.; M.L.G.I.; N.B.; M.J.E.; F.L.; L.B. (Laura Barcán); M.L.; A.R.; L.T., F.P. (Fernando Pasterán); A.C.; M.R. (Melina Rapoport); F.N.; M.C.G.D.; R.C.; R.M.; M.R. (Mariana Reynaldi); G.G.; M.B. (Marcelo Bronzi); S.V.; M.L.C.; V.V. and M.B. (Miriam Blanco); data curation, D.T. and A.Á.C.; writing—original draft preparation, F.H.; writing—review and editing, D.T., A.Á.C., F.P. (Fernando Poletta) and F.P. (Fernando Pasterán); funding acquisition, F.H. and A.Á.C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by a Norberto Quirno Foundation scholarship and the Infectious Diseases Society of Argentina. None of these institutions participated in the study design, sample collection, analysis and data interpretation or in the decision to submit the manuscript for publication. Only the authors had full access to the study data files.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the CEMIC Ethics Committee on 30 April 2014 (Approval identification number 880) and the ethics committees from the different participating institutions.

Informed Consent Statement

Patient participation in this study was voluntary, and a written informed consent was required up until December 2016. Thereafter, patient consent was waived by the Ethics Committees since this study continued as a registry of statistic, epidemiological, and scientific data, according to the Data Protection Law 25326, Section 7, Subsection 2.

Data Availability Statement

Data is available upon request. Contact the corresponding author.

Acknowledgments

We thank Valeria Melia for the English edition of the manuscript. We thank The Infectious Diseases Society of Argentina for their financial support of this publication. Members of ROCAS group: Fabián Herrera, Diego Torres, Ana Laborde, Lorena Berruezo, Rosana Jordán, Inés Roccia Rossi, Alejandra Valledor, Patricia Costantini, Miguel Dictar, Andrea Nenna, María Laura Pereyra, Sandra Lambert, José Benso, Fernando Poletta, María Luz Gonzalez Ibañez, Nadia Baldoni, María José Eusebio, Fiorella Lovano, Laura Barcán, Martín Luck, Agustina Racioppi, Lucas Tula, Fernando Pasterán, Alejandra Corso, Melina Rapoport, Federico Nicola, María Cristina García Damiano, Ruth Carbone, Renata Monge, Mariana Reynaldi, Graciela Greco, Marcelo Bronzi, Sandra Valle, María Laura Chaves, Viviana Vilches, Miriam Blanco and Alberto Ángel Carena.

Conflicts of Interest

Fabián Herrera received speaker honoraria from MSD and Pfizer and a research and educational grant from Pfizer. Fernando Pasterán received speaker honoraria from MSD and Pfizer. Sandra Lambert received speaker honoraria from Pfizer. The rest of the authors declare no conflicts of interest.

Appendix A

Table
Table A1. Number of patients included in each center and resistant mechanisms in CRE isolates.
Table A1. Number of patients included in each center and resistant mechanisms in CRE isolates.
Center1234 *56789 *101112Total
Patients included
n7166607264458189313419443
%16.014.913.51.65.99.913.14.12.07.07.74.3100
CRE
n102130113150012259
%14.13.021.70.03.829.525.90.00.03.25.910.513.3
blaKPC
n10213019150002254
%14.13.021.70.03.820.425.90.00.00.05.910.512.2
blaOXA
n0000040001005
%000009.10003.2001.1
* Centers incorporated into the study since 2018. Abbreviation: CRE, carbapenem-resistant Enterobacterales.
Table
Table A2. Stage of underlying cancer and immunosuppression in ST, HM and HSCT patients.
Table A2. Stage of underlying cancer and immunosuppression in ST, HM and HSCT patients.
VariablesHM
n = 266
n (%)		HSCT
n = 85
n (%)		ST
n = 92
n (%)		p-Value *
Stage of underlying cancer
Recently diagnosed130 (48.9)4 (4.7)25 (27.2)<0.0001
Complete remission25 (9.4)48 (56.5)3 (3.3)<0.0001
Partial remission23 (8.6)13 (15.3)26 (28.3)<0.0001
Refractory27 (10.2)7 (8.2)12 (13)0.56
Relapse61 (22.9)13 (15.3)26 (28.3)0.11
Recent chemotherapy (1 month prior to bacteremia)193 (72.6)59 (69.4)80 (87)0.01
Recent radiotherapy (1 month prior to bacteremia)9 (3.4)8 (9.4)14 (15.2)<0.0001
Receiving steroids during bacteremia96 (36.1)32 (37.6)22 (23.9)0.07
Receiving biological agents27 (10.2)19 (22.4)6 (6.5)0.002
* Centers incorporated into the study since 2018. Abbreviation: HM, hematologic malignancy; HSCT, hematopoietic stem cell transplant; ST, solid tumor.

References

  1. Bush, K.; Bradford, P.A. Epidemiology of β-Lactamase-Producing Pathogens. Clin. Microbiol. Rev. 2020, 33, e00047-19. [Google Scholar] [CrossRef] [PubMed]
  2. Capone, A.; Giannella, M.; Fortini, D.; Giordano, A.; Meledandri, M.; Ballardini, M.; Venditti, M.; Bordi, E.; Capozzi, D.; Balice, M.P.; et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin. Microbiol. Infect. 2013, 19, E23–E30. [Google Scholar] [CrossRef] [Green Version]
  3. Castanheira, M.; Deshpande, L.M.; Mendes, R.E.; Canton, R.; Sader, H.S.; Jones, R.N. Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. Open Forum Infect. Dis. 2019, 6 (Suppl. S1), S23–S33. [Google Scholar] [CrossRef] [Green Version]
  4. García-Betancur, J.C.; Appel, T.M.; Esparza, G.; Gales, A.C.; Levy-Hara, G.; Cornistein, W.; Vega, S.; Nuñez, D.; Cuellar, L.; Bavestrello, L.; et al. Update on the epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev. Anti-Infect. Ther. 2021, 19, 197–213. [Google Scholar] [CrossRef]
  5. Thomas, G.R.; Corso, A.; Pasterán, F.; Shal, J.; Sosa, A.; Pillonetto, M.; de Souza Peral, R.T.; Hormazábal, J.C.; Araya, P.; Saavedra, S.Y.; et al. Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic. Emerg. Infect. Dis. 2022, 28, 1–8. [Google Scholar] [CrossRef]
  6. Villegas, M.V.; Pallares, C.J.; Escandón-Vargas, K.; Hernández-Gómez, C.; Correa, A.; Álvarez, C.; Rosso, F.; Matta, L.; Luna, C.; Zurita, J.; et al. Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries. PLoS ONE 2016, 11, e0154092. [Google Scholar] [CrossRef] [Green Version]
  7. Averbuch, D.; Tridello, G.; Hoek, J.; Mikulska, M.; Akan, H.; Yanez San Segundo, L.; Pabst, T.; Özçelik, T.; Klyasova, G.; Donnini, I.; et al. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin. Infect. Dis. 2017, 65, 1819–1828. [Google Scholar] [CrossRef]
  8. Trecarichi, E.M.; Pagano, L.; Candoni, A.; Pastore, D.; Cattaneo, C.; Fanci, R.; Nosari, A.; Caira, M.; Spadea, A.; Busca, A.; et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey. Clin. Microbiol. Infect. 2015, 21, 337–343. [Google Scholar] [CrossRef] [Green Version]
  9. Herrera, F.; Laborde, A.; Jordán, R.; Berruezo, L.; Roccia Rossi, I.; Valledor, A.; Lambert, S.; Pereyra, M.; Nenna, A.; Dictar, M.; et al. Current Epidemiology of Bacteremia in Patients with Hematological Malignancies and Hematopoietic Stem Cell Transplantation and the Impact of Antibiotic Resistance on Survival. In Proceedings of the 31st of European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Vienna, Austria, 9–12 July 2021. [Google Scholar]
  10. Tofas, P.; Skiada, A.; Angelopoulou, M.; Sipsas, N.; Pavlopoulou, I.; Tsaousi, S.; Pagoni, M.; Kotsopoulou, M.; Perlorentzou, S.; Antoniadou, A.; et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. Int. J. Antimicrob. Agents 2016, 47, 335–339. [Google Scholar] [CrossRef]
  11. Freire, M.P.; Pierrotti, L.C.; Filho, H.H.; Ibrahim, K.Y.; Magri, A.S.; Bonazzi, P.R.; Hajar, L.; Diz, M.P.; Pereira, J.; Hoff, P.M.; et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur. J. Clin. Microbiol. Infect. Dis. 2015, 34, 277–286. [Google Scholar] [CrossRef] [PubMed]
  12. Girmenia, C.; Rossolini, G.M.; Piciocchi, A.; Bertaina, A.; Pisapia, G.; Pastore, D.; Sica, S.; Severino, A.; Cudillo, L.; Ciceri, F.; et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: A nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015, 50, 282–288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Trecarichi, E.M.; Pagano, L.; Martino, B.; Candoni, A.; Di Blasi, R.; Nadali, G.; Fianchi, L.; Delia, M.; Sica, S.; Perriello, V.; et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: Clinical impact of carbapenem resistance in a multicentre prospective survey. Am. J. Hematol. 2016, 91, 1076–1081. [Google Scholar] [CrossRef] [PubMed]
  14. Herrera, F.; Laborde, A.; Torre, V.; Jordán, R.; Roccia Rossi, I.; Valledor, A.; Costantini, P.; Dictar, M.; Nenna, A.; Caeiro, J.P.; et al. Bacteremia due to Enterobacteriaceae in cancer patients: Etiology, clinical features and outcome depending on antimicrobial resistance. Data from ROCAS Study. In Proceedings of the 29th of European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Amsterdam, The Netherlands, 13–16 April 2019. [Google Scholar]
  15. Girmenia, C.; Bertaina, A.; Piciocchi, A.; Perruccio, K.; Algarotti, A.; Busca, A.; Cattaneo, C.; Raiola, A.M.; Guidi, S.; Iori, A.P.; et al. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clin. Infect. Dis. 2017, 65, 1884–1896. [Google Scholar] [CrossRef] [PubMed]
  16. Micozzi, A.; Gentile, G.; Minotti, C.; Cartoni, C.; Capria, S.; Ballarò, D.; Santilli, S.; Pacetti, E.; Grammatico, S.; Bucaneve, G.; et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: Factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect. Dis. 2017, 17, 203. [Google Scholar] [CrossRef] [Green Version]
  17. Satlin, M.J.; Cohen, N.; Ma, K.C.; Gedrimaite, Z.; Soave, R.; Askin, G.; Chen, L.; Kreiswirth, B.N.; Walsh, T.J.; Seo, S.K. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J. Infect. 2016, 73, 336–345. [Google Scholar] [CrossRef] [Green Version]
  18. Giannella, M.; Pascale, R.; Gutiérrez-Gutiérrez, B.; Cano, A.; Viale, P. The use of predictive scores in the management of patients with carbapenem-resistant Klebsiella pneumoniae infection. Expert Rev. Anti-Infect. Ther. 2019, 17, 265–273. [Google Scholar] [CrossRef]
  19. Giannella, M.; Trecarichi, E.M.; De Rosa, F.G.; Del Bono, V.; Bassetti, M.; Lewis, R.E.; Losito, A.R.; Corcione, S.; Saffioti, C.; Bartoletti, M.; et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: A prospective observational multicentre study. Clin. Microbiol. Infect. 2014, 20, 1357–1362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Cano, A.; Gutiérrez-Gutiérrez, B.; Machuca, I.; Gracia-Ahufinger, I.; Pérez-Nadales, E.; Causse, M.; Castón, J.J.; Guzman-Puche, J.; Torre-Giménez, J.; Kindelán, L. Risks of Infection and Mortality Among Patients Colonized with Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Validation of Scores and Proposal for Management. Clin. Infect. Dis. 2018, 66, 1204–1210. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Giannella, M.; Bartoletti, M.; Morelli, M.C.; Tedeschi, S.; Cristini, F.; Tumietto, F.; Pasqualini, E.; Danese, I.; Campoli, C.; Lauria, N.D.; et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: The importance of pre- and posttransplant colonization. Am. J. Transplant. 2015, 15, 1708–1715. [Google Scholar] [CrossRef]
  22. Zhang, P.; Wang, J.; Hu, H.; Zhang, S.; Wei, J.; Yang, Q.; Qu, T. Clinical Characteristics and Risk Factors for Bloodstream Infection Due to Carbapenem-Resistant Klebsiella pneumoniae in Patients with Hematologic Malignancies. Infect. Drug Resist. 2020, 13, 3233–3242. [Google Scholar] [CrossRef]
  23. Wang, Y.; Lin, Q.; Chen, Z.; Hou, H.; Shen, N.; Wang, Z.; Wang, F.; Sun, Z. Construction of a Risk Prediction Model for Subsequent Bloodstream Infection in Intestinal Carriers of Carbapenem-Resistant Enterobacteriaceae: A Retrospective Study in Hematology Department and Intensive Care Unit. Infect. Drug Resist. 2021, 14, 815–824. [Google Scholar] [CrossRef]
  24. Wu, Q.; Qian, C.; Yin, H.; Liu, F.; Wu, Y.; Li, W.; Xia, L.; Ma, L.; Hong, M. A Novel Risk Predictive Scoring Model for Predicting Subsequent Infection After Carbapenem-Resistant Gram-Negative Bacteria Colonization in Hematological Malignancy Patients. Front. Oncol. 2022, 12, 897479. [Google Scholar] [CrossRef]
  25. Falcone, M.; Bassetti, M.; Tiseo, G.; Giordano, C.; Nencini, E.; Russo, A.; Graziano, E.; Tagliaferri, E.; Leonildi, A.; Barnini, S.; et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit. Care 2020, 24, 29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Paul, M.; Carrara, E.; Retamar, P.; Tängdén, T.; Bitterman, R.; Bonomo, R.A.; de Waele, J.; Daikos, G.L.; Akova, M.; Harbarth, S.; et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin. Microbiol. Infect. 2022, 28, 521–547. [Google Scholar] [CrossRef] [PubMed]
  27. Tamma, P.D.; Aitken, S.L.; Bonomo, R.A.; Mathers, A.J.; van Duin, D.; Clancy, C.J. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin. Infect. Dis. 2021, 72, e169–e183. [Google Scholar] [CrossRef]
  28. van Duin, D.; Lok, J.J.; Earley, M.; Cober, E.; Richter, S.S.; Perez, F.; Salata, R.A.; Kalayjian, R.C.; Watkins, R.R.; Doi, Y.; et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin. Infect. Dis. 2018, 66, 163–171. [Google Scholar] [CrossRef] [Green Version]
  29. Tumbarello, M.; Raffaelli, F.; Giannella, M.; Mantengoli, E.; Mularoni, A.; Venditti, M.; De Rosa, F.G.; Sarmati, L.; Bassetti, M.; Brindicci, G.; et al. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clin. Infect. Dis. 2021, 73, 1664–1676. [Google Scholar] [CrossRef]
  30. Tsolaki, V.; Mantzarlis, K.; Mpakalis, A.; Malli, E.T.; Tsimpoukas, F.; Tsirogianni, A.; Papagiannitsis, C.; Zygoulis, P.; Papadonta, M.E.; Petinaki, E.; et al. Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients. Antimicrob. Agents Chemother. 2020, 64, e02320-19. [Google Scholar] [CrossRef]
  31. Castón, J.J.; Lacort-Peralta, I.; Martín-Dávila, P.; Loeches, B.; Tabares, S.; Temkin, L.; Torre-Cisneros, J.; Paño-Pardo, J.R. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int. J. Infect. Dis. 2017, 59, 118–123. [Google Scholar] [CrossRef] [Green Version]
  32. Meng, H.; Han, L.; Niu, M.; Xu, L.; Xu, M.; An, Q.; Lu, J. Risk Factors for Mortality and Outcomes in Hematological Malignancy Patients with Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Infect. Drug Resist. 2022, 15, 4241–4251. [Google Scholar] [CrossRef]
  33. Mularoni, A.; Martucci, G.; Douradinha, B.; Campanella, O.; Hazen, B.; Medaglia, A.; Arena, G.; Gruttadauria, S.; Tuzzolino, F.; Arcadipane, A.; et al. Epidemiology and successful containment of a carbapenem-resistant Enterobacteriaceae outbreak in a Southern Italian Transplant Institute. Transpl. Infect. Dis. 2019, 21, e13119. [Google Scholar] [CrossRef]
  34. Pillinger, K.E.; Bouchard, J.; Withers, S.T.; Mediwala, K.; McGee, E.U.; Gibson, G.M.; Bland, C.M.; Bookstaver, P.B. Inpatient Antibiotic Stewardship Interventions in the Adult Oncology and Hematopoietic Stem Cell Transplant Population: A Review of the Literature. Ann. Pharmacother. 2020, 54, 594–610. [Google Scholar] [CrossRef]
  35. Battipaglia, G.; Malard, F.; Rubio, M.T.; Ruggeri, A.; Mamez, A.C.; Brissot, E.; Giannotti, F.; Dulery, R.; Joly, A.C.; Baylatry, M.T.; et al. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. Haematologica 2019, 104, 1682–1688. [Google Scholar] [CrossRef] [Green Version]
  36. Pession, A.; Zama, D.; Muratore, E.; Leardini, D.; Gori, D.; Guaraldi, F.; Prete, A.; Turroni, S.; Brigidi, P.; Masetti, R. Fecal Microbiota Transplantation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review. J. Pers. Med. 2021, 11, 100. [Google Scholar] [CrossRef]
  37. Freifeld, A.G.; Bow, E.J.; Sepkowitz, K.A.; Boeckh, M.J.; Ito, J.I.; Mullen, C.A.; Raad, I.I.; Rolston, K.V.; Young, J.A.; Wingard, J.R.; et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2011, 52, e56–e93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Friedman, N.D.; Kaye, K.S.; Stout, J.E.; McGarry, S.A.; Trivette, S.L.; Briggs, J.P.; Lamm, W.; Clark, C.; MacFarquhar, J.; Walton, A.L.; et al. Health care-associated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. 2002, 137, 791–797. [Google Scholar] [CrossRef] [PubMed]
  39. Harris, P.N.A.; Tambyah, P.A.; Lye, D.C.; Mo, Y.; Lee, T.H.; Yilmaz, M.; Alenazi, T.H.; Arabi, Y.; Falcone, M.; Bassetti, M.; et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E. coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA 2018, 320, 984–994, Erratum in JAMA 2019, 321, 2370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef] [Green Version]
  41. Perez, F.; Adachi, J.; Bonomo, R.A. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin. Infect. Dis. 2014, 59 (Suppl. S5), S335–S339. [Google Scholar] [CrossRef]
  42. Protocolo de PCR-Multiplex Para la Detección de Carbapenemasas. Available online: http://antimicrobianos.com.ar/2019/10/protocolo-de-pcr-multiplex-para-la-deteccion-de-carbapenemasas/ (accessed on 30 November 2022).
  43. Gutiérrez-Gutiérrez, B.; Salamanca, E.; de Cueto, M.; Hsueh, P.R.; Viale, P.; Paño-Pardo, J.R.; Venditti, M.; Tumbarello, M.; Daikos, G.; Pintado, V.; et al. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clin. Proc. 2016, 91, 1362–1371, Erratum in Mayo Clin. Proc. 2016, 91, 1843. [Google Scholar] [CrossRef]
Antibiotics 12 00226 g001 550
Figure 1. Etiology of Enterobacterales bacteremia. Differences between carbapenem-susceptible Enterobacterales (CSE) and carbapenem-resistant Enterobacterales (CRE) isolates.
Figure 1. Etiology of Enterobacterales bacteremia. Differences between carbapenem-susceptible Enterobacterales (CSE) and carbapenem-resistant Enterobacterales (CRE) isolates.
Antibiotics 12 00226 g001
Antibiotics 12 00226 g002 550
Figure 2. Resistance mechanisms of Enterobacterales. Proportion of extended-spectrum β-lactamases (ESBL) and Amp-C producers in carbapenem-susceptible Enterobacterales (CSE) isolates. Proportion of blaKPC and blaOXA-48 in carbapenem-resistant Enterobacterales (CRE) isolates.
Figure 2. Resistance mechanisms of Enterobacterales. Proportion of extended-spectrum β-lactamases (ESBL) and Amp-C producers in carbapenem-susceptible Enterobacterales (CSE) isolates. Proportion of blaKPC and blaOXA-48 in carbapenem-resistant Enterobacterales (CRE) isolates.
Antibiotics 12 00226 g002
Table
Table 1. Baseline characteristics of patients with carbapenem-susceptible Enterobacterales (CSE) and carbapenem-resistant Enterobacterales (CRE) bacteremia.
Table 1. Baseline characteristics of patients with carbapenem-susceptible Enterobacterales (CSE) and carbapenem-resistant Enterobacterales (CRE) bacteremia.
VariablesCSE
n = 384
n (%)		CRE
n = 59
n (%)		p-Value *
Age (years) (median, IQR)55.5 (37–66)51 (39–64)0.31
Male gender216 (56.3)35 (59.3)0.65
Inclusion criteria
Hematologic malignancy226 (58.8)40 (67.8)0.19
Solid malignancy89 (23.2)3 (5.1)0.001
Hematopoietic Stem Cell Transplant69 (18)16 (27.1)0.09
Stage of underlying cancer
Recently diagnosed126 (32.8)33(55.9)0.001
Complete remission65 (17)11(18.6)0.74
Partial remission57 (14.8)5 (8.5)0.23
Refractory43 (11.2)3 (5.1)0.17
Relapse93 (24.2)7 (11.9)0.03
Recent chemotherapy (1 month prior to bacteremia)290 (75.5)42 (71.2)0.47
Recent radiotherapy (1 month prior to bacteremia)28 (7.3)3 (5.1)0.78
Receiving steroids during bacteremia125 (32.5)35 (59.3)0.13
Charlson comorbidity index (median, IQR)2 (2–3)2 (2–3)0.21
Neutropenia258 (67.2)52 (88.1)0.001
High risk by MASCC score222 (86)49 (94.2)0.10
Neutropenia duration (days) (IQR)11 (6–19)16 (10–24)0.004
Recent hospitalization (1 month prior to bacteremia)204 (53.1)32 (54.2)0.87
Recent antibiotic use (1 month prior to bacteremia)158 (41.1)45 (76.3)<0.001
Fluoroquinolone prophylaxis64 (16.7)13 (22)0.31
Abbreviation: MASCC, Multinational Association for Supportive Care in Cancer. * p-Values obtained by chi-square or Fisher’s exact test for categorical variables, and Mann–Whitney U-test for continuous variables. Bold: statistically significant.
Table
Table 2. Clinical presentation, treatment, and outcome of carbapenem-susceptible Enterobacterales (CSE) and carbapenem-resistant Enterobacterales (CRE) bacteremia.
Table 2. Clinical presentation, treatment, and outcome of carbapenem-susceptible Enterobacterales (CSE) and carbapenem-resistant Enterobacterales (CRE) bacteremia.
VariablesCSE
n (%)		CRE
n (%)		p-Value *
Nosocomial infection241 (62.8)55 (93.2)<0.001
Bacteremia with clinical source286 (74.5)34 (57.6)0.007
Abdominal115 (29.9)14 (23.7)0.32
Central venous catheter40 (10.4)10 (16.9)0.14
Urinary tract55 (14.3)2 (3.4)0.02
Adequate EAT352 (91.7)28 (47.5)<0.001
Empirical antibiotic monotherapy283 (73.6)38 (64.4)0.13
Combined definitive antibiotic treatment22 (5.7)57 (96.6)<0.001
APACHE II score the day of bacteremia (median, IQR)13 (9–17)12 (8–17)0.16
PITT score the day of bacteremia (median, IQR)0 (0–2)0 (0–2)0.39
Intensive care unit admission required86 (22.4)29 (49.1)<0.001
Shock development83 (21.6)30 (50.8)<0.001
Breakthrough bacteremia20 (5.2)14 (23.7)<0.001
7-day mortality45 (11.7)21 (35.6)<0.001
Infection-related37 (82.2)21 (100)0.03
30-day mortality68 (17.7)32 (54.2)<0.001
Infection-related47 (69.1)27 (84.4)0.08
More than 24-h delay in adequate antibiotic treatment27 (7)26 (44.1)<0.001
Abbreviation: EAT, empirical antibiotic treatment. * p-values obtained by chi-square or Fisher’s exact test for categorical variables, and Mann–Whitney U-test for continuous variables. Bold: statistically significant.
Table
Table 3. Risk factors for carbapenem-resistant bacteremia and points assigned to the score.
Table 3. Risk factors for carbapenem-resistant bacteremia and points assigned to the score.
VariablesUnivariate Analysis Multivariate Analysis Points
OR (95%CI)p-ValueOR (95%CI)p-Value
Recent carbapenems use4.1 (2.3–7.7)0.001
>7 days of antibiotic use prior to bacteremia4.6 (2.6–4.1)0.0014.65 (2.29–9.46)<0.0012
Neutropenia3.6 (1.6–8.2)0.002
≥10-days of hospitalization prior to bacteremia4.4 (2.3–8.6)0.0014.03 (1.88–8.66)<0.0012
Recent intensive care unit admission3 (1.4–6.8)0.006
Central venous catheter in place3.4 (1.7–6.7)0.002
Previous colonization with KPC-CPE10.6 (4.4–25.5)0.001
Recent colonization with KPC-CPE24.9 (1.3–55)0.00133.08 (11.7–93.25)<0015
Abbreviation: KPC-CPE, KPC-carbapenemase-producing Enterobacterales.
Table
Table 4. Sensitivity, specificity, and post-test probability of the different cut-off points of the score.
Table 4. Sensitivity, specificity, and post-test probability of the different cut-off points of the score.
Point of the ScoreSensitivitySpecificity+LR−LRPositive
Post-Test Probability		Negative
Post-Test Probability
≥0100.00%0.00%1 13.30%
≥294.92%40.21%1.58740.126519.58%1.90%
≥476.27%83.81%4.71160.283141.95%4.16%
≥542.37%97.13%14.75350.593369.36%8.34%
≥735.59%98.43%22.72040.654377.71%9.12%
≥920.34%99.22%25.96620.802979.93%10.97%
>90.00%100.00% 10.00%13.30%
Abbreviations: +LR, positive likelihood ratio; -LR, negative likelihood ratio.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Herrera, F.; Torres, D.; Laborde, A.; Berruezo, L.; Jordán, R.; Rossi, I.R.; Valledor, A.; Costantini, P.; Dictar, M.; Nenna, A.; et al. Development of a Clinical Score to Stratify the Risk for Carbapenem-Resistant Enterobacterales Bacteremia in Patients with Cancer and Hematopoietic Stem Cell Transplantation. Antibiotics 2023, 12, 226. https://doi.org/10.3390/antibiotics12020226

AMA Style

Herrera F, Torres D, Laborde A, Berruezo L, Jordán R, Rossi IR, Valledor A, Costantini P, Dictar M, Nenna A, et al. Development of a Clinical Score to Stratify the Risk for Carbapenem-Resistant Enterobacterales Bacteremia in Patients with Cancer and Hematopoietic Stem Cell Transplantation. Antibiotics. 2023; 12(2):226. https://doi.org/10.3390/antibiotics12020226

Chicago/Turabian Style

Herrera, Fabián, Diego Torres, Ana Laborde, Lorena Berruezo, Rosana Jordán, Inés Roccia Rossi, Alejandra Valledor, Patricia Costantini, Miguel Dictar, Andrea Nenna, and et al. 2023. "Development of a Clinical Score to Stratify the Risk for Carbapenem-Resistant Enterobacterales Bacteremia in Patients with Cancer and Hematopoietic Stem Cell Transplantation" Antibiotics 12, no. 2: 226. https://doi.org/10.3390/antibiotics12020226

APA Style

Herrera, F., Torres, D., Laborde, A., Berruezo, L., Jordán, R., Rossi, I. R., Valledor, A., Costantini, P., Dictar, M., Nenna, A., Pereyra, M. L., Lambert, S., Benso, J., Poletta, F., Gonzalez Ibañez, M. L., Baldoni, N., Eusebio, M. J., Lovano, F., Barcán, L., ... Carena, A. Á., on behalf of the Argentine Group for the Study of Bacteremia in Cancer and Stem Cell Transplant (ROCAS) Study. (2023). Development of a Clinical Score to Stratify the Risk for Carbapenem-Resistant Enterobacterales Bacteremia in Patients with Cancer and Hematopoietic Stem Cell Transplantation. Antibiotics, 12(2), 226. https://doi.org/10.3390/antibiotics12020226

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop